Mercator MedSystems, Inc.

Mercator MedSystems, Inc. develops innovative medical devices, including the Bullfrog micro-infusion device, which ensures localized delivery of therapeutic agents for improved treatment outcomes in vascular conditions. Mercator MedSystems, Inc. was founded in 1999 and is headquartered in Emeryville, US.

The company specializes in creating medical devices that focus on localized drug delivery. Kirk Seward is the founder, and the current CEO is Trent Reutiman. The company has raised a total of USD 3. 18 mn, with its latest funding round being Series D, attracting investments from Salubris.

Mercator has conducted five deals in total, with its current valuation at USD 99. 061 mn. Mercator MedSystems, Inc. specializes in developing innovative medical devices, particularly the Bullfrog micro-infusion device.

This core offering facilitates the local delivery of the anti-inflammatory drug dexamethasone directly to target sites within the body, such as the perivenous area in patients suffering from acute deep vein thrombosis (DVT). The device enhances treatment outcomes by improving blood vessel patency and reducing post-thrombotic syndrome (PTS). Primarily used in interventional angiographic settings, the Bullfrog device allows for efficient localized therapy while minimizing systemic side effects associated with conventional drug delivery methods. The company's products are marketed mainly in the United States, Europe, and select international regions to healthcare providers, hospitals, and clinics involved in vascular treatment and management.

Mercator MedSystems generates revenue through the sale of its micro-infusion devices and associated therapeutics, focusing on partnerships with healthcare institutions and direct transactions with healthcare providers. The flagship product, the Bullfrog micro-infusion device, is sold primarily through a direct sales model, allowing healthcare facilities to purchase devices in bulk for treating patients with conditions like DVT. In addition to device sales, the company engages in collaborative agreements with clinical research organizations to validate product efficacy, enhancing market credibility and driving future sales. Transaction structures often involve one-time purchases or negotiated contracts based on volume, with pricing varying according to agreement specifics and healthcare provider needs.

As the company expands its clinical trial efforts and product offerings, it aims to strengthen its revenue stream through strategic partnerships and direct sales channels. Mercator MedSystems, Inc. is focused on launching new products that enhance their micro-infusion technology. The company plans to expand into new markets, targeting Europe and Asia by the end of 2024.

Recent funding raised from M&L Healthcare will support these initiatives, including the development of upcoming devices designed to improve therapeutic delivery in vascular treatments.